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Chronic heart failure is not going away, but continues to expand globally. This is largely driven by new cases of heart 
failure with preserved ejection fraction. Patients receive chronic disease management complicated by frequent hospi-
talizations to treat episodes of exacerbation that not only affect quality of life but is also associated with a signifi cant 
fi nancial burden to the society. With a better understanding of heart failure pathophysiology, our management strategy 
has shifted progressively from reactive to preventive, such as daily weight monitoring and interaction with specialized 
nurses. With the advent of new technology, non-invasive remote monitoring is now more available with regular, auto-
matic data transmission to the health care center, including heart rate, blood pressure, weight and daily activity. The 
widespread use of implanted cardioverter defi brillators and cardiac resynchronization therapy in patients with heart 
failure has enabled the expansion of these devices with various indwelling sensors aimed at monitoring volume status 
and predicting need for hospitalization. As the success of this approach was noted to be limited, implantable hemody-
namic sensors have been subsequently developed in an attempt to reduce heart failure hospitalizations and mortality. 
This manuscript provides a brief review and clinical utility of the available remote monitoring approaches and devices 
for patients with heart failure. 
Újabb lehetőségek a telemonitorozás és a krónikus szívelégtelenség ambuláns kezelésében
A krónikus szívelégtelenség incidenciája világszerte emelkedik elsődlegesen az újonnan diagnosztizált megtartott 
ejekciós frakciójú szívelégtelenségben szenvedő betegek magas számának köszönhetően. A szívelégtelen betegek 
krónikus ellátást és gyakori kórházi kezelést igényelnek, amely nemcsak az életminőségre van negatív hatással, de a 
társadalomra is jelentős anyagi terhet ró. A szívelégtelenség patofi ziológiájának megismerésével párhuzamosan terá-
piás stratégiánk egyre inkább a reaktív felől a preventív felé tolódott, mint például a testsúly napi követése és a szíve-
légtelenség ellátásában jártas nővérekkel való rendszeres kapcsolattartás. A technológia fejlődésével noninvaziv tele-
monitorozás is lehetővé vált, amely rendszeresen és automatikusan továbbít bizonyos paramétereket az egészségügyi 
centrumba, mint például szívfrekvencia, vérnyomás, testsúly és napi aktivitás. A defi brillátorok és reszinkronizációs 
terápia elterjedése lehetővé tette különböző szenzorok integrálását, amelyek alkalmasak lehetnek a folyadékfelesleg 
monitorozására és emiatti kórházi felvétel szükségességének előre történő megjóslására. Mivel ezen módszerek sikere 
limitáltnak bizonyult, implantálható hemodinamikai monitorok kerültek kifejlesztésre, melyek használata a szívelégte-
lenség miatti halálozás és kórházi felvételek számának csökkenéséhez vezetett. Ezen közlemény a szívelégtelen-
ségben szenvedő betegpopuláció számára rendelkezésre álló invazív és noninvazív telemonitorozási lehetőségeket, 
valamint az ezekkel elért eredményeket foglalja össze.
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szívelégtelenség, telemonitorozás, hemodinamikai monitorok, halálozásKulcsszavak:
101
Cardiologia Hungarica Alexy–Francis: Telemonitoring and Contemporary Outpatient Management of Patients
Epidemiology and pathophysiology of 
heart failure
Chronic heart failure (HF) is currently estimated to 
affect over 38 million adults worldwide (1), a prominent 
surge from 23 million in the 1990s (2). Despite impro-
ved preventive and therapeutic strategies, it’s prevalen-
ce is projected to increase by an additional 46% by 
2030 (3). In the United States (U.S.) alone, 5.7 million 
adults suffer from symptomatic disease currently (3) 
and over 500,000 new patients are diagnosed with HF 
annually. Based on studies performed in the U.S. and 
f the leading diagnoses for hospitalizations and re-hos-
pitalizations; more than 20% of patients are re admit-
ted within 30 days of discharge and 50% by 6 months 
(7, 8). Frequent HF hospitalizations not only affect the 
patient’s quality of life but also represent a major fi nan-
cial burden to the society with the total cost estimated 
to exceed $70 billion in the U.S. by 2030 (9). While not 
all HF-related healthcare expenditures are preventab-
le, multiple strategies and novel medical devices have 
been developed aiming to reduce hospital admissions 
and emergency room/offi ce visits without compromisi-
ng patient safety. This has required an improved under-
standing of HF pathophysiology and the identifi cation of 
milestones whereby early intervention could reduce the 
risk of further decompensation.
The most common reason for acute HF exacerbation 
is congestion rather than a rapid, unexpected decline 
in cardiac output. Despite the signifi cant structural and 
functional differences between HF with reduced ejec-
tion fraction (HFrEF) and HF with preserved ejection 
fraction (HFpEF), rising fi lling pressures play a pivotal 
role in the pathophysiology of decompensation in both 
syndromes (10). Using implantable pressure monitors, 
subtle but persistent changes can be detected up to 4 
weeks prior to hospitalization (11). Within 7 days the-
re is a prominent shift in the balance of the autonomic 
nervous system with sympathetic activation and redu-
ced parasympathetic tone. These initial compensatory 
mechanisms lead to increased inotropy, chronotropy, 
vasoconstriction, activation of the renin-angiotensin 
system and further fl uid retention. The increased int-
ravascular hydrostatic pressure commonly leads to in-
terstitial fl uid accumulation in the lungs as well as the 
periphery overwhelming the lymphatic system (12). In 
some cases, there is simply a translocation of splanch-
nic fl uid to the thorax without increase in weight. These 
changes are usually documented 1-2 weeks prior to ad-
mission and are accompanied by a decrease in thora-
cic impedance. Without a change in diuretic regimen, 
ongoing fl uid retention can often, but not always, lead 
to a detectable increase in body weight. Clinical signs 
and symptoms of decompensated HF develop within 
approximately 7 days, ultimately prompting patients to 
seek medical attention.
As we gain a better understating of the pathophysio-
logy of HF, non-invasive methods as well as invasive 
sensors have been developed aiming to recognize and 
block the progression of HF exacerbation at an increa-
singly earlier stage. Our approach has shifted from be-
ing reactive to a more preventive posture by detecting 
the earliest electronic signals of decompensation via 
implanted instrumentation. The following sections pro-
vide a brief overview of the utility, benefi ts and disad-
vantages of various interventions and devices that are 
currently at our disposal.
Remote monitoring approaches and devices
Non-invasive remote monitoring
Initial attempts to reduce HF hospitalizations were di-
rected at home based, non-invasive telemonitoring. 
These efforts included symptomatic evaluation using 
structured telephone support (STS) and the use of 
electronic devices with digital transmission of simp-
le physiological variables such as weight, heart rate, 
blood pressure and ECG to the health care team on 
a regular basis. The clinical, economical and behavi-
oral benefi ts of non-invasive telemonitoring has been 
evaluated in numerous single center and large case 
multicenter trials with their fi ndings summarized in 
multiple meta-analyses. While some studies descri-
bed a benefi t from these approaches in reducing 
HF-hospitalizations and mortality (13), other studies 
failed to confi rm a positive impact. 2 kg increase in 
body weight over a period of 48 hours, for example, 
had a sensitivity of merely 9% and showed no close 
correlation with intracardiac fi lling pressures (14). This 
is not unexpected as fl uid sometimes simply translo-
cates from the splanchnic vascular bed to the thoracic 
veins. Selected trials focusing on different physiologi-
cal metrics with positive and negative outcomes are 
listed in Table 1.
Device-based monitoring
Based on guideline recommendations for patients 
with HFrEF, the use of implanted cardioverter defi b-
rillators (ICDs) and cardiac resynchronization therapy 
(CRT) has increased dramatically in recent years. This 
opened up the opportunity to build in thoracic volume 
sensors into these devices in an attempt to predict im-
pending HF decompensation. Monitored parameters 
commonly include heart rate variability, incidence of ar-
rhythmias, daily physical activity level, sleep patterns 
and thoracic impedance, each of which demonstrates 
an inverse relationship with pulmonary capillary wedge 
pressure (15). Multiple randomized trials and meta-ana-
lyses were published in the fi eld with variable results 
regarding the clinical utility of these implanted devices. 
Selected papers with negative and positive fi ndings are 
listed in Table 2.
Given the variable success with the approaches detai-
led above, a new device algorithm was recently devel-
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oped combining input from multiple sensors monitoring 
various aspects of HF pathophysiology. The hypothesis 
was tested in the international, multicenter, non-rando-
mized MultiSENSE study (16). Collected data included 
respiratory rate, relative tidal volume, heart rate, heart 
sounds focusing on S3, patient activity and thoracic 
impedance. The HeartLogic algorithm was able to de-
tect HF decompensation with a median lead time of 34 
days, a sensitivity of 70% and an unexplained alert rate 
of only 1.47 per patient year. Further studies are under-
way to establish if widespread use of this novel algorit-
hm would reduce HF-related hospitalizations, healthca-
re costs, mortality and its impact on quality of life.
Implantable hemodynamic monitors
Better understanding of HF pathophysiology has also 
led to the development of implantable hemodynamic 
sensors to monitor fi lling pressures. The Chronicle de-
vice (Medtronic Inc, Minneapolis, MN) was designed 
to measure systolic and diastolic right ventricular (RV) 
pressure and to estimate pulmonary artery (PA) dias-
tolic pressure using a lead secured in the RV outfl ow 
tract (17). The COMPASS-HF was a multicenter, sing-
le-blinded, randomized, parallel-controlled study de-
signed to evaluate if hemodynamic monitoring with the 
Chronicle device would reduce the composite endpoint 
of HF-related hospitalizations and the need for IV diure-
tic therapy (18). Hemodynamic data were downloaded 
and transmitted weekly but the heart failure team could 
only review these for the treatment group. Compared 
to the controls, there was a 21% reduction in the total 
event rate with monitoring. Yet, the difference did not 
reach statistical signifi cance. This may be explained 
by the lack of pre-specifi ed pressure targets and that 
TABLE 1. Selected trials evaluating the efficacy of non-invasive telemonitoring. Green square indicates positive results red squa-
re marks studies with negative results BP: blood pressure; ECG: electrocardiogram; QOL: quality of life
Trial Parameters monitored Findings
WISH (37) Weight No effect on cardiac re-hospitalization, mortality
TEHAF (38) Symptoms, health behaviors No effect on mortality, HF-hospitalizations
TEMA-HF1 (39) Weight, BP, heart rate Reduced mortality, hospitalizations
SPAN-CHF II (40) BP, heart rate, weight, symptoms, adherence Reduced 90-days hospitalizations
DIAL (41) Weight, symptoms, adherence, activity Reduced HF-admissions
TEN-HMS (42) Weight, BP, heart rate and rhythm No effect on admission, reduced mortality
TIM-HF (43) ECG, BP, weight No effect on HF-hospitalization or mortality
INH (44) Signs and symptoms, nurse coordinated management No effect on mortality and re-hospitalization
TELE-HF (45) Symptoms, weight No effect on 180-days re-admissions, mortality
BEAT-HF (46) BP, heart rate, weight, symptoms No effect on 180-days re-admissions
IN TOUCH (47) Weight, BP, blood pressure, symptoms No effect on HF-hospitalization, mortality QOL
Kingston-upon-Hull (48) Weight and diastolic BP Predicted HF-admissions (Measured over 8 days)
TABLE 2. Selected trials evaluating the utility of device-based therapies in reducing HF outcomes. Green square indicates posi-
tive results, red square marks studies with negative results HRV: Heart Rate Variability; OptiVolTM: Proprietary algorhythm to 
measure electrical impedance between the device can and RV electrode (Medtronic, Inc.)
Trial Parameters monitored Findings
IN-TIME (49) Reduced activity, arrhythmias Reduced mortality, no effect on HF-hospitalizations
PARTNERS-HF (50) Arrhythmias, activity, OptiVolTM, HRV Predicted HF-hospitalizations
SENSE-HF (51) OptiVolTM Low sensitivity and predictive value for HF-hospitalization
MORE-CARE (52) OptiVolTM and arrhythmias No effect on mortality or HF-hospitalizations but reduced in-offi ce visits
REM-HF (53) Multiple parameters No effect on mortality or HF-hospitalizations
EVOLVO (54) Multiple parameters Reduced heart care utilization
DOT-HF (55) Multiple parameters No effect on outcomes and increased HF-hospitalizations
COMPAS (56) HRV, arrhythmias Reduced ambulatory clinic visits
TRUST (57) Arrhythmias Reduced health care utilization
OPTILINK (58) Volume status No effect on outcomes
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medical therapy was not adjusted in response to the 
PA diastolic pressures. However, there was a signifi -
cant 36% reduction in the relative risk of HF-associa-
ted hospitalizations and the treatment effect was more 
pronounced in patients with NYHA Class III symptoms. 
Due to the overall negative study results, the Food and 
Drug Administration voted against the approval of the 
Chronicle device.
Given the limited but encouraging success of Chronic-
le, a new, implantable, battery-free, wireless hemody-
namic monitoring system (CardioMems™, Abbott, Min-
neapolis, MN) was developed. The sensor is implanted 
during a minimally invasive right heart catheterization 
with the aim to detect early, subtle changes in intracar-
diac and PA pressures. Sensor data were shown to cor-
relate well with hemodynamic measurements obtained 
during simultaneous Swan-Ganz catheterization as 
well as Doppler echocardiographic assessments (19). 
CHAMPION, a prospective, single-blind, multicenter 
trial enrolled 550 patients with NYHA Class III HF sy-
mptoms with at least one hospitalization in the previous 
year, regardless of etiology or EF and randomly assig-
ned them to guideline-directed optimal medical therapy 
with or without CardioMems ™ monitoring (20). In addi-
tion to frequent clinic visits, PA pressures were monito-
red daily. Diuretic regimen and vasodilator therapy were 
adjusted based on the hemodynamic data, following a 
strict, pre-defi ned study protocol. While the trial was not 
powered to detect direct impact on mortality, the group 
managed using CardioMems ™ data had a signifi cant 
28% reduction in HF hospitalizations at 6 months and 
37% at 15 months. A post-hoc analysis of the patient 
subgroup with HFrEF (EF<40%, 445 patients) and on 
maximal medical therapy revealed a signifi cant reduc-
tion in mortality after initiating PA pressure-guided HF 
management (21). In addition, there was a signifi cant 
drop in 30-day all cause readmission rates as well 
as an improvement in quality of life (22). Utilizing the 
Cardio Mems ™ system was shown to be cost effective 
to the U.S. healthcare system in the “real-world” setting 
with the benefi ts sustained at 1 year (23, 24). It gai-
ned FDA approval in 2014 with the indication to reduce 
HF hospitalizations. These devices are costly, but so 
are frequent hospitalizations that they may prevent. It is 
too early to know if more wide-spread use of implanted 
pressure sensing devices will ensue.
OnTrack patient self-management system
A new, innovative iPad-based application, called OnT-
rack to Health, goes beyond remote monitoring. It was 
developed based on the observation that self-manage-
ment is of critical importance for patients with chronic 
HF. Serving as major drivers for decompensation, the 
rates of dietary indiscretion and medication non adher-
ence may reach, or even surpass, 50% in this patient 
population (25–28). The system is designed to promote 
patient engagement, active decision making and comp-
liance by providing individualized daily reminders and 
teaching materials. At the same time, it allows for se-
cure, real-time, two-way communication with the healt-
hcare team. This feature is particularly important for 
patients living in remote areas with no easy access to 
medical care. Full integration with electronic medical re-
cord systems and remote monitoring equipment is on-
going. Based on initial experience, the OnTrack Health 
system improves patient satisfaction with health care 
delivery, quality of life and reduces HF-related hospi-
talizations.
Innovative outpatient volume management 
strategies
Once congestion is detected by one of the remote 
monitoring strategies, patient contact and rapid inter-
vention are of critical importance. As intestinal edema 
progresses with rising fi ling pressures, the absorption 
and effi cacy of oral medications often decline, despite 
dosing escalation. Developing novel outpatient approa-
ches and strategies to deliver adequate doses of diure-
tics are essential in order to reduce the risk of hospital 
admission. While several ideas have been proposed 
and tested, we will review the utility of outpatient diu-
retic infusion clinics and subcutaneous furosemide ad-
ministration.
Outpatient diuretic infusion clinics
The mainstay of HF therapy continues to be intravenous 
loop diuretic administration with no signifi cant differen-
ce between the effi cacy of continuous infusion and bo-
lus dosing (29, 30). In response to fi nancial incentives 
to reduce the expenditures associated with chronic HF 
management, driven primarily by expensive emergency 
room visits and hospitalizations, many healthcare sy-
stems have established outpatient clinics specialized 
in intravenous (IV) loop diuretic administration. Using 
standardized protocols, this approach has been shown 
to represent a safe and effective alternative to hospi-
tal admissions in selected, hemodynamically stable 
patients with mild to moderate heart failure exacerba-
tion across a wide spectrum of EF (31). Reported side 
effects, including hypokalemia and worsening renal fa-
ilure were transient and rare (31). While approximately 
one third of the population may eventually require ad-
mission and intensifi ed HF management (32), 30-day 
readmission rates were shown to decrease by 10% 
(33) and patients spend 3 fewer days on average in the 
hospital per every 6 months, leading to an estimated 
annular saving of $12,000 (34). Overall these fi ndings 
suggest that outpatient IV diuretic administration to a 
selected group of HF patients is safe and improves qu-
ality of life while reducing health care expenses. More 
of these clinics are now appearing in the U.S. with inc-
reasingly favorable results.
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Subcutaneous furosemide therapy
Aiming to further reduce healthcare utilization and 
to improve quality of life, a novel, pH-neutral subcu-
taneous formulation of furosemide has recently been 
developed. In a small, phase II, proof of concept stu-
dy, a total of 80 mg furosemide was injected under the 
skin over 5 hours using an automated infusion pump 
(35). Upon direct comparison to a dose adjusted, single 
traditional IV furosemide injection, the new formulation 
provided comparable urine output with a more sustai-
ned diuretic effect. Subcutaneous furosemide was well 
tolerated with no evidence for worsening renal function 
or skin irritation. Importantly, thirty-day hospitalization 
rates for acute HF exacerbation was similar between 
the two treatment arms. Further studies with the no-
vel furosemide formulation and the delivery pump are 
ongoing. It is conceivable that selected patients may 
eventually use this strategy at home, with guidance 
from the medical team, to reduce HF symptoms to the 
point that emergency room visit and hospital admission 
will not be necessary (36).
Conclusions
Management of patients with HF remains a major chal-
lenge to providers worldwide. Advances in technology 
enabled remote monitoring of a wide range of physio-
logical variables by multidisciplinary health care teams. 
However, telemonitoring alone did not improve outco-
mes or reduce expenditures as described by several 
studies. It is the combination of monitoring, timely data 
interpretation and protocol-driven therapeutic intervent-
ions that prevent decompensation and may lead to a 
decline in HF admissions, mortality as well as health 
care expenses. The importance of self-management, 
with continuous assistance from the HF team, is increa-
singly recognized and improves outcomes. Novel ma-
nagement strategies, such as outpatient diuretic clinics 
and home subcutaneous furosemide infusion, may also 
reduce hospitalizations. Further studies and innovative 
management strategies are needed to reduce the bur-
den of HF over the next decade.
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